RESEARCH PROFILE
IGF-1 LR3
Long Arg3 Insulin-Like Growth Factor-1 • Growth Factor & Cellular Signaling Research
IGF-1 LR3 is a synthetic, long-acting analog of insulin-like growth factor-1 (IGF-1), a naturally occurring protein involved in growth, metabolism, and cellular signaling.
Research involving IGF-1 LR3 focuses on IGF-1 receptor activation, protein synthesis, cellular proliferation, glucose metabolism, and the biological pathways associated with tissue growth and development.
The compound has been modified to alter its interaction with IGF-binding proteins and extend its biological activity compared with native IGF-1.
INVESTIGATIONAL COMPOUND • NOT FDA APPROVED • NO ESTABLISHED HUMAN CLINICAL DOSING
IGF-1 LR3 AT A GLANCE
Category
Hormonal & Growth Factor Research
Compound
Long Arg3 Insulin-Like Growth Factor-1
Compound Type
Synthetic, long-acting IGF-1 analog
Primary Research Focus
Growth factor signaling • Protein synthesis • Cellular proliferation • Glucose metabolism • Tissue growth biology
Primary Biological Target
Insulin-Like Growth Factor-1 Receptor (IGF-1R)
Principal Signaling Pathways
PI3K–Akt–mTOR • RAS–RAF–MEK–ERK
Reported Biological Half-Life
Approximately 20–30 hours in research references, compared with approximately 12–15 hours for circulating native IGF-1. Human pharmacokinetics have not been clinically established for IGF-1 LR3.
Evidence Base
Primarily laboratory and preclinical animal research
Human Clinical Evidence
No published human clinical trial establishing the safety or efficacy of IGF-1 LR3 identified in the Project source
Regulatory Status
Not FDA approved for any human therapeutic indication
IMPORTANT DISTINCTION
IGF-1 LR3 is not the same compound as native IGF-1 or mecasermin (Increlex).
Mecasermin is an FDA-approved recombinant human IGF-1 medication for specific pediatric growth disorders.
IGF-1 LR3 is a structurally modified research analog with different binding characteristics and prolonged biological activity.
Clinical evidence or regulatory approval involving mecasermin cannot automatically be transferred to IGF-1 LR3.
IGF-1 LR3 has no established human therapeutic dose, approved indication, or validated clinical safety profile.
WHAT IS IGF-1 LR3?
IGF-1 LR3, also known as Long Arg3 IGF-1, is a synthetic analog of insulin-like growth factor-1.
IGF-1 is a naturally occurring growth factor produced primarily in response to growth hormone signaling.
It participates in normal biological processes involving:
Cellular growth
Protein synthesis
Tissue development
Glucose regulation
Muscle and connective-tissue biology
Cell survival and differentiation
IGF-1 LR3 was developed to modify the behavior of native IGF-1.
STRUCTURAL MODIFICATIONS
IGF-1 LR3 contains two principal structural changes.
Arginine Substitution
An arginine residue replaces the glutamic acid normally present at position 3 of native IGF-1.
N-Terminal Extension
An additional 13 amino acids are attached to the beginning of the molecule.
Together, these modifications produce an 83-amino-acid analog rather than the 70-amino-acid structure of native IGF-1.
WHY THESE MODIFICATIONS MATTER
Native IGF-1 circulates in association with IGF-binding proteins.
These proteins influence its distribution, availability, and biological activity.
IGF-1 LR3 was engineered to interact less strongly with certain IGF-binding proteins.
This altered binding behavior can increase the amount of unbound analog available to interact with IGF-1 receptors in experimental systems.
The compound is also associated with a longer duration of biological activity.
RESEARCH APPLICATIONS
IGF-1 LR3 is investigated in connection with:
Growth factor receptor signaling
Protein synthesis pathways
Muscle-cell biology
Cellular proliferation
Metabolic signaling
Glucose uptake
Tissue growth and remodeling
These are areas of biological investigation, not established clinical benefits.
IMPORTANT DISTINCTION
IGF-1 LR3 does not simply increase the body's natural production of growth hormone.
It acts more directly on the IGF-1 signaling pathway.
This distinguishes it from growth hormone secretagogues such as ipamorelin, sermorelin, and CJC-1295.
MECHANISM OF ACTION
IGF-1 LR3 primarily acts through the insulin-like growth factor-1 receptor, or IGF-1R.
IGF-1R is a receptor tyrosine kinase found in many tissues throughout the body.
When activated, it initiates intracellular signaling pathways involved in growth, metabolism, and cellular survival.
IGF-1 RECEPTOR ACTIVATION
IGF-1 LR3 binds to IGF-1 receptors and activates downstream signaling.
Two major pathways are particularly relevant.
PI3K–AKT–MTOR SIGNALING
The PI3K–Akt–mTOR pathway is involved in:
Protein synthesis
Cellular growth
Nutrient signaling
Glucose transport
Cell survival
Regulation of protein breakdown
Activation of this pathway provides part of the mechanistic rationale for studying IGF-1 analogs in muscle and tissue-growth biology.
However, activation of a protein-synthesis pathway does not establish that IGF-1 LR3 safely increases muscle mass or improves athletic performance in humans.
RAS–RAF–MEK–ERK SIGNALING
The RAS–RAF–MEK–ERK pathway participates in:
Cellular proliferation
Cell differentiation
Growth signaling
Cell-cycle regulation
Responses to growth factors
This pathway is important in normal tissue biology.
It is also relevant to cancer research because excessive growth signaling can contribute to abnormal cellular proliferation.
GLUCOSE METABOLISM
IGF-1 signaling can influence glucose uptake and insulin-related metabolic processes.
This creates an important safety consideration.
Excessive IGF-related activity may contribute to hypoglycemia, or abnormally low blood glucose.
REDUCED IGF-BINDING PROTEIN AFFINITY
The structural modifications in IGF-1 LR3 reduce its affinity for certain IGF-binding proteins.
In experimental systems, this can increase receptor-accessible compound exposure.
It also makes IGF-1 LR3 pharmacologically different from native IGF-1.
PROLONGED BIOLOGICAL ACTIVITY
The Project profile describes an approximately 20–30-hour research half-life.
This prolonged activity is one reason IGF-1 LR3 is discussed separately from shorter-acting IGF-1 preparations.
However, this estimate should not be treated as a validated human pharmacokinetic value.
IMPORTANT MECHANISM LIMITATION
IGF-1 receptor activation is a well-established biological process.
The clinical safety and therapeutic effectiveness of administering IGF-1 LR3 to humans have not been established.
Mechanistic plausibility does not demonstrate a safe or effective human treatment.
WHAT THE RESEARCH SHOWS
OVERALL EVIDENCE
The research surrounding IGF-1 LR3 is primarily preclinical.
Published studies have investigated its biological activity in laboratory systems and animal models.
The Project source does not identify a published human clinical trial establishing the efficacy or safety of IGF-1 LR3.
PRECLINICAL POTENCY RESEARCH
Tomas and colleagues, 1995
Research involving modified IGF-1 analogs examined differences in biological potency, body-weight responses, organ growth, and metabolic activity.
The Project profile reports that IGF-1 LR3 demonstrated greater activity than native IGF-1 in certain experimental measurements.
These findings are relevant to growth factor pharmacology.
They do not establish an effective or safe human dose.
ANABOLIC SIGNALING RESEARCH
Tomas and colleagues, 1992
Preclinical research examined the effects of IGF-1 analogs on anabolic responses and protein metabolism.
The findings contributed to interest in modified IGF-1 compounds as tools for investigating tissue growth and protein turnover.
However, animal anabolic responses cannot be assumed to predict human muscle growth, recovery, or athletic performance.
MUSCLE BIOLOGY
IGF-1 receptor signaling participates in muscle-cell growth and adaptation.
Experimental research has examined relationships involving:
Muscle protein synthesis
Satellite-cell activity
Cell differentiation
Tissue growth
Anabolic signaling
Protein turnover
These mechanisms explain why IGF-1 LR3 appears in muscle-related research discussions.
They do not establish that IGF-1 LR3 improves human strength, hypertrophy, or recovery.
GLUCOSE AND METABOLIC RESEARCH
IGF-1-related compounds can influence glucose regulation.
This is biologically significant because the same metabolic activity that makes IGF signaling an area of research can create clinically important risks.
Human studies of the approved IGF-1 medication mecasermin demonstrate that IGF-related treatment can cause hypoglycemia.
Those studies provide relevant pathway-level safety context, but they are not direct clinical studies of IGF-1 LR3.
CANCER-PATHWAY RESEARCH
IGF-1 signaling is involved in cellular proliferation and survival.
Research has examined the relationship between IGF signaling and several types of cancer.
The Project profile references experimental findings in which IGF-1 LR3 influenced tumor-related biological activity.
This does not prove that IGF-1 LR3 causes cancer in humans.
It does establish a meaningful biological concern that requires caution when evaluating prolonged or excessive growth-factor signaling.
HUMAN CLINICAL EVIDENCE
The Project source identifies no published human clinical trial establishing IGF-1 LR3 as safe or effective for any therapeutic or performance-related indication.
Human research involving native IGF-1 or mecasermin cannot be treated as equivalent evidence for IGF-1 LR3.
IMPORTANT EVIDENCE LIMITATION
There is no established human clinical evidence demonstrating that IGF-1 LR3:
Increases muscle mass safely
Improves athletic performance
Accelerates injury recovery
Reverses aging
Improves body composition
Enhances tissue repair
Provides a favorable long-term risk-benefit profile
These remain unvalidated claims when applied to IGF-1 LR3.
SAFETY & RESEARCH CONSIDERATIONS
IGF-1 LR3 has no established human clinical safety profile.
Because the compound directly affects growth factor signaling, its potential risks extend beyond ordinary injection-related concerns.
HYPOGLYCEMIA
One of the most important potential risks is low blood glucose.
IGF-1-related activity can increase glucose uptake and influence insulin-related metabolic processes.
The Project profile references clinically significant hypoglycemia in patients receiving mecasermin, an FDA-approved form of native recombinant IGF-1.
Reported complications in that separate clinical population have included severe hypoglycemia and seizures.
These findings cannot be used to calculate the incidence of hypoglycemia with IGF-1 LR3, but they establish an important pathway-related concern.
Potential symptoms of hypoglycemia include:
Sweating
Shakiness
Rapid heartbeat
Dizziness
Weakness
Confusion
Loss of consciousness
Seizures
Severe confusion, seizures, or loss of consciousness require emergency medical attention.
ABNORMAL TISSUE GROWTH
IGF-1 signaling influences cellular proliferation and tissue growth.
Excessive stimulation may create concerns involving abnormal tissue responses.
The Project profile discusses related findings from clinical experience with mecasermin, including tonsillar and lymphoid tissue enlargement.
These findings should not be interpreted as measured adverse-event rates for IGF-1 LR3.
INTRACRANIAL HYPERTENSION
Intracranial hypertension has been reported with approved IGF-1 therapy.
Symptoms may include:
Persistent or severe headache
Visual disturbances
Nausea
Vomiting
New or persistent headaches, particularly with visual changes, warrant prompt medical evaluation.
FLUID RETENTION
IGF-related treatments may be associated with:
Edema
Joint discomfort
Headache
Fluid retention
The incidence and severity of these effects with IGF-1 LR3 have not been established in controlled human studies.
CANCER-RELATED CONCERNS
IGF-1 signaling participates in cell proliferation and survival.
These functions are important for normal growth and repair but are also relevant to tumor biology.
The Project source identifies active cancer, prior cancer, and significant cancer history as major areas of concern.
This does not establish that IGF-1 LR3 causes cancer.
It means that the compound's growth-signaling activity raises biologically meaningful safety questions.
ORGAN GROWTH
IGF-1-related signaling affects multiple tissues.
The Project profile discusses organ-growth concerns based on experimental findings and clinical observations involving related IGF-1 therapies.
Long-term organ effects from IGF-1 LR3 exposure in humans remain unknown.
ENDOCRINE FEEDBACK
IGF-1 participates in feedback regulation of the growth hormone axis.
Exogenous IGF-1-related activity may alter normal hormonal signaling.
The extent of these effects with IGF-1 LR3 has not been established in controlled human trials.
INTERACTIONS WITH OTHER COMPOUNDS
Potential interaction concerns are especially relevant when IGF-1 LR3 is combined with:
Insulin
Sulfonylureas
Other glucose-lowering medications
Growth hormone
Growth hormone secretagogues
Other IGF-related compounds
Combining substances that influence glucose regulation or growth signaling may increase biological complexity and risk.
No validated human clinical safety studies establish the safety of these combinations with IGF-1 LR3.
INJECTION AND PRODUCT-QUALITY RISKS
Research-market injectable products can introduce additional risks involving:
Contamination
Incorrect identity
Incorrect concentration
Sterility failures
Endotoxin exposure
Mislabeling
Storage instability
Injection-site reactions
A product described as research grade is not necessarily manufactured or verified to pharmaceutical standards.
PREGNANCY & BREASTFEEDING
There is insufficient human safety information regarding IGF-1 LR3 during pregnancy or breastfeeding.
IMPORTANT SAFETY DISTINCTION
Human safety data for mecasermin do not establish the safety of IGF-1 LR3.
IGF-1 LR3 has different structural and pharmacological properties, and its long-term human risks remain unknown.
REGULATORY CONTEXT
IGF-1 LR3 IS NOT FDA APPROVED
IGF-1 LR3 is not approved by the U.S. Food and Drug Administration for any human therapeutic indication.
The Project profile identifies no approved human drug application for IGF-1 LR3.
It has no FDA-established prescribing information, approved dosing schedule, or authorized therapeutic indication.
DISTINCTION FROM MECASERMIN
Mecasermin, marketed as Increlex, is a recombinant human IGF-1 medication.
It is FDA approved for certain pediatric patients with severe primary IGF-1 deficiency.
IGF-1 LR3 is a different molecule.
Approval of mecasermin does not constitute approval of IGF-1 LR3.
RESEARCH MARKET STATUS
IGF-1 LR3 is commonly described in research-market materials as an investigational compound.
A research-use label does not establish that a product is suitable, lawful, or approved for human administration.
COMPOUNDING CONTEXT
The Project profile does not identify IGF-1 LR3 as an FDA-approved drug or an established, eligible ingredient for routine human prescription compounding.
Compounding rules and ingredient eligibility are separate from FDA drug approval.
ANTI-DOPING STATUS
The Project profile identifies IGF-1 and its analogs, including IGF-1 LR3, as prohibited under World Anti-Doping Agency rules.
These restrictions are relevant to athletes participating in drug-tested competition.
IMPORTANT REGULATORY DISTINCTION
IGF-1 LR3 is not FDA approved.
Mecasermin approval does not extend to IGF-1 LR3.
Research-use labeling does not establish human safety or legal authorization for therapeutic use.
Preclinical potency does not establish clinical efficacy.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation for specific samples and lots represented in its research library.
IGF-1 LR3 1 MG
The Croix Project catalog identifies:
IGF-1 LR3 — 1 mg
LOT SPECIFIC ANALYTICAL DOCUMENTATION
Analytical documentation is displayed only when Croix has a corresponding laboratory report that can be matched to the specific product and lot.
No matching IGF-1 LR3 1 mg COA is currently displayed.
IMPORTANT COA LIMITATION
When analytical documentation becomes available, results should be presented only for the specific sample and lot identified in the laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix's Project standard specifically requires matching the product, strength, lot or batch, sample ID, laboratory, and report date before analytical documentation is presented.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
IGF-1 LR3 PHARMACOLOGY
Tomas FM, et al.
Research examining the biological potency of modified IGF-1 analogs with altered binding-protein interactions.
Preclinical research relevant to the pharmacological differences between IGF-1 LR3 and native IGF-1.
Tomas FM, et al.
Research examining the anabolic activity of IGF-1 analogs in experimental animal models.
Preclinical evidence involving protein metabolism and tissue-growth responses.
IGF-1 SIGNALING & CANCER BIOLOGY
LeRoith D, Roberts CT Jr.
The Insulin-Like Growth Factor System and Cancer.
Cancer Letters. 2003.
Review examining IGF-related signaling and its relationship with cancer biology.
Pollak M.
Insulin and Insulin-Like Growth Factor Signalling in Neoplasia.
Nature Reviews Cancer. 2008.
Review of insulin and IGF signaling pathways relevant to tumor development and progression.
IGF-1 RECEPTOR & METABOLIC BIOLOGY
Siddle K.
Research examining insulin and insulin-like growth factor receptor signaling.
Background literature on receptor activation, intracellular signaling, and metabolic regulation.
CLINICAL SAFETY CONTEXT
U.S. Food & Drug Administration
Increlex (mecasermin) Prescribing Information.
Official prescribing information for recombinant human IGF-1, including hypoglycemia warnings and other clinically documented risks.
This reference concerns mecasermin, not IGF-1 LR3.
ANTI-DOPING REFERENCE
World Anti-Doping Agency
The Prohibited List.
Official anti-doping restrictions relevant to IGF-1 and its analogs.
EVIDENCE NOTE
These references provide scientific context involving IGF-1 LR3, related IGF-1 analogs, receptor signaling, and approved IGF-1 therapy.
They do not establish the clinical efficacy or safety of IGF-1 LR3 in humans.
No published human clinical trial identified in the Project source has established IGF-1 LR3 as a safe or effective treatment for muscle growth, recovery, body composition, aging, or any other human indication.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish IGF-1 LR3 as safe or effective for personal use.
IGF-1 LR3 is a synthetic, long-acting analog of insulin-like growth factor-1 investigated for its effects on growth factor receptor signaling, protein synthesis, cellular proliferation, and metabolic pathways.
Its structural modifications distinguish it from native IGF-1 and the FDA-approved prescription medication mecasermin.
The available evidence is primarily laboratory and preclinical. IGF-1 LR3 is not FDA approved, and no published human clinical trial identified in the Project source has established its safety, efficacy, or appropriate human dosing.
Potential risks include hypoglycemia, abnormal growth signaling, and other effects associated with IGF-related pathways. The long-term consequences of human IGF-1 LR3 exposure remain unknown.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.